Evolving role of galectin-3 as a cardiac biomarker: heart failure with preserved ejection fraction and renal function, important pieces of the puzzle.

Christopher R deFilippi, Robert H Christenson

Abstract readEditorialComment

In one paragraph

Article in JACC. Heart failure, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it

0cells of the map it votes in

6citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

Novel Biomarkers in Heart Failure: New Insight in Pathophysiology and Clinical Perspective.Journal of clinical medicine · 2021
Review
Galectin-3 and Risk of Late Graft Failure in Kidney Transplant Recipients: A 10-year Prospective Cohort Study.Transplantation · 2021
Observational
Higher galectin-3 levels are independently associated with lower anxiety in patients with risk factors for heart failure.BioPsychoSocial medicine · 2020
Article
Galectin-3 Reflects the Echocardiographic Grades of Left Ventricular Diastolic Dysfunction.Annals of laboratory medicine · 2018
Article
Immune Modulation in Heart Failure: the Promise of Novel Biologics.Current treatment options in cardiovascular medicine · 2018
Review
Vascular dysfunction and fibrosis in stroke-prone spontaneously hypertensive rats: The aldosterone-mineralocorticoid receptor-Nox1 axis.Life sciences · 2017
Article

4 · The record

Corrections and comments

Comment on
Galectin-3 in heart failure with preserved ejection fraction. A RELAX trial substudy (Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure).2015

5 · Who and what money

Authors and funding

2 authors.

Christopher R deFilippiDivision of Cardiovascular Medicine, University of Maryland School of Medicine, Baltimore, Maryland. Electronic address: cdefilip@medicine.umaryland.edu.

Robert H ChristensonDepartment of Pathology, University of Maryland School of Medicine, Baltimore, Maryland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Exercise ToleranceFemaleGalectin 3Heart Failure, DiastolicHumansMalePhosphodiesterase 5 InhibitorsStroke VolumeVentricular Function, LeftGalectin 3Phosphodiesterase 5 Inhibitorscardiac biomarkerejection fractiongalectin-3renal function

Identifiers

PMID25742763

DOI10.1016/j.jchf.2014.12.009

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.